Uckun, F.M.; Watts, J.; Mims, A.S.; Patel, P.; Wang, E.; Shami, P.J.; Cull, E.; Lee, C.; Cogle, C.R.; Lin, T.L.
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers 2021, 13, 5287.
https://doi.org/10.3390/cancers13215287
AMA Style
Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin TL.
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers. 2021; 13(21):5287.
https://doi.org/10.3390/cancers13215287
Chicago/Turabian Style
Uckun, Fatih M., Justin Watts, Alice S. Mims, Prapti Patel, Eunice Wang, Paul J. Shami, Elizabeth Cull, Cynthia Lee, Christopher R. Cogle, and Tara L. Lin.
2021. "Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436" Cancers 13, no. 21: 5287.
https://doi.org/10.3390/cancers13215287
APA Style
Uckun, F. M., Watts, J., Mims, A. S., Patel, P., Wang, E., Shami, P. J., Cull, E., Lee, C., Cogle, C. R., & Lin, T. L.
(2021). Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers, 13(21), 5287.
https://doi.org/10.3390/cancers13215287